オプティアム・バイオテクノロジーズ株式会社
6 known investors
Find your way into オプティアム・バイオテクノロジーズ株式会社
Sign up to see every warm intro you have to オプティアム・バイオテクノロジーズ株式会社
- Paths you didn't know you had: your email and LinkedIn already hold routes to the オプティアム・バイオテクノロジーズ株式会社 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Optieum develops next-generation CAR-T cell therapies using a proprietary CAR discovery platform to optimize immune cell activation for treating solid tumors and hematological malignancies. The company engineers precision CAR constructs to enhance T-cell therapeutic efficacy.
Investors · 6
How we know: Hiroshima Venture Capital Co. Ltd.'s portfolio page · Not right? Tell us
How we know: Iyogin Capital's portfolio page · Not right? Tell us
How we know: Keio Innovation Initiative's portfolio page · Not right? Tell us
How we know: Kobe University Capital's portfolio page · Not right? Tell us
Related companies · 5
Companies working in the same space as オプティアム・バイオテクノロジーズ株式会社.
Frequently asked questions
- What does オプティアム・バイオテクノロジーズ株式会社 do?
- Optieum develops next-generation CAR-T cell therapies using a proprietary CAR discovery platform to optimize immune cell activation for treating solid tumors and hematological malignancies. The company engineers precision CAR constructs to enhance T-cell therapeutic efficacy.
- Who are オプティアム・バイオテクノロジーズ株式会社's investors?
- オプティアム・バイオテクノロジーズ株式会社's investors include Hiroshima Venture Capital Co. Ltd., Iyogin Capital, Keio Innovation Initiative, Kobe University Capital, UntroD Capital, Vision Incubate.



